{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.","groups":[{"description":"Patients diagnosed with Indolent B-cell NHL","id":"OG000","title":"Cohort 1"},{"description":"Patients diagnosed with Mantle Cell NHL","id":"OG001","title":"Cohort 2"},{"description":"Patients diagnosed with T Cell NHL","id":"OG002","title":"Cohort 4"}],"paramType":"NUMBER","populationDescription":"Response indicated for Indolent B-cell NHL, Mantle cell NHL and T-cell NHL","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Lymphoid/Plasma Cell Malignancies","type":"PRIMARY","unitOfMeasure":"patients"}